NDTVCenter·
This Dengue Vaccine Aspirant's Stock Has Rallied Over 40% In Five Sessions
Much of this momentum is being driven by investors cheering the launch of the DENSTAR (Dengue Efficacy and Safety Trial in African Region) project.
Read at NDTV →
Business · 1 sources covering this
This Dengue Vaccine Aspirant's Stock Has Rallied Over 40% In Five Sessions
Much of this momentum is being driven by investors cheering the launch of the DENSTAR (Dengue Efficacy and Safety Trial in African Region) project.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/dde34f01b9fe0ecd350011394d2b0ee59581fb7d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="This Dengue Vaccine Aspirant's Stock Has Rallied Over 40% In Five Sessions"></iframe>
